{"id":"masitinib-6-0","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Gastrointestinal disorders (nausea, diarrhea, abdominal pain)"},{"rate":"20-40","effect":"Rash"},{"rate":"10-20","effect":"Edema"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"10-20","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Masitinib inhibits multiple tyrosine kinases involved in mast cell and immune cell signaling, particularly c-Kit and PDGF receptors. By blocking these pathways, it reduces mast cell degranulation and inflammatory mediator release, thereby modulating immune responses in inflammatory and neurodegenerative conditions. This mechanism allows it to address both the immune component and neuroinflammation in diseases like amyotrophic lateral sclerosis and other inflammatory disorders.","oneSentence":"Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGF receptor, and Lyn kinase to modulate immune cell activation and reduce inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:11.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"},{"name":"Pancreatic cancer"},{"name":"Mastocytosis"},{"name":"Severe asthma"}]},"trialDetails":[{"nctId":"NCT03127267","phase":"PHASE3","title":"Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients","status":"RECRUITING","sponsor":"AB Science","startDate":"2021-02-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":495},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT05047783","phase":"PHASE2","title":"Masitinib in Patients With Symptomatic Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2021-11-23","conditions":"Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019","enrollment":78},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT00812240","phase":"PHASE3","title":"Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)","status":"TERMINATED","sponsor":"AB Science","startDate":"2009-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":335},{"nctId":"NCT03771040","phase":"PHASE3","title":"Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels","status":"COMPLETED","sponsor":"AB Science","startDate":"2016-12","conditions":"Asthma","enrollment":347},{"nctId":"NCT01410695","phase":"PHASE2, PHASE3","title":"Masitinib in Refractory Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"AB Science","startDate":"2011-07","conditions":"Rheumatoid Arthritis (RA)","enrollment":324}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AB1010"],"phase":"phase_3","status":"active","brandName":"Masitinib (6.0)","genericName":"Masitinib (6.0)","companyName":"AB Science","companyId":"ab-science","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Masitinib is a medication being studied for the treatment of Mast Cell Activation Syndrome, Covid-19, SARS-CoV-2 Infection, Coronavirus Disease 2019, and Indolent Systemic Mastocytosis. It is administered at a dose of 4.5 mg/kg/day in clinical trials, and is being developed by AB Science.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}